Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cipla
Colorcon
Boehringer Ingelheim
Moodys
Johnson and Johnson
Farmers Insurance
Daiichi Sankyo
McKinsey

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,440,922

« Back to Dashboard

Which drugs does patent 9,440,922 protect, and when does it expire?

Patent 9,440,922 protects ALECENSA and is included in one NDA.

This patent has forty patent family members in thirty-five countries.
Summary for Patent: 9,440,922
Title:Tetracyclic compound
Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: ##STR00001## (meanings of the symbols that are included in the formula are as given in the specification).
Inventor(s): Kinoshita; Kazutomo (Kanagawa, JP), Asoh; Kohsuke (Kanagawa, JP), Furuichi; Noriyuki (Kanagawa, JP), Ito; Toshiya (Kanagawa, JP), Kawada; Hatsuo (Kanagawa, JP), Ishii; Nobuya (Kanagawa, JP), Sakamoto; Hiroshi (Kanagawa, JP), Hong; WooSang (Gyeonggi-do, KR), Park; MinJeong (Gyeonggi-do, KR), Ono; Yoshiyuki (Shizuoka, JP), Kato; Yasuharu (Shizuoka, JP), Morikami; Kenji (Shizuoka, JP), Emura; Takashi (Shizuoka, JP), Oikawa; Nobuhiro (Kanagawa, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:14/619,242
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,440,922

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,440,922

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,126,931 Tetracyclic compound ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,440,922

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2011154150 ➤ Try a Free Trial
Serbia 20110548 ➤ Try a Free Trial
Portugal 2441753 ➤ Try a Free Trial
Poland 2441753 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Argus Health
Teva
Deloitte
Express Scripts
McKinsey
Accenture
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.